课题基金 / 基金详情

PROTOCOL REVIEW AND MONITORING SYSTEM (Core 012)

PROTOCOL REVIEW AND MONITORING SYSTEM (Core 012)
方案审查和监测系统(核心 012)
批准号:
9359377
负责人:
SYMA IQBAL
金额:
$13.77万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至

项目摘要

项目成果

SYMA IQBAL的其他基金

相似基金

相关文献

中文摘要
翻译
项目总结/文摘
英文摘要
Project Summary/Abstract The USC Norris Protocol Review and Monitoring System (PRMS) has two organizational components, the Clinical Investigations Committee (CIC) and the Scientific Progress and Accrual Monitoring Subcommittee. During the project period, PRMS has been significantly improved, resulting in reduced turnaround time and fewer low accruing trials. Members of the CIC now represent a broad range of scientific disciplines and the clear majority is senior investigators. To assure quality reviews, we have clarified member selection criteria and term limit policies. We have also increased the frequency of CIC meetings and attendance rates, enhanced scientific review and prioritization processes, improved written communications with PIs, and added maximum PI response times to reduce delays. A new operational and financial review process has been added and integrated into the PRMS workflow to assure operational feasibility without increasing turnaround. These and other improvements have improved quality in the initial scientific review process and halved time to PRMS approval, which averages four weeks. To enhance scientific monitoring of approved trials and to close trials that are not achieving their enrollment targets more quickly, we formed a dedicated Scientific Progress and Accrual Monitoring Subcommittee. The resulting structure completely separates scientific review and quality assurance. With this organizational change, an existing accrual monitoring policy was tightened so that we can close trials that are consuming institutional resources and are not enrolling at a reasonable pace. In summary, the current PRMS process is highly effective in selecting and supporting investigator initiated trials and recent changes having a very positive impact on both quality and efficiency. Additional improvements will be achieved as OnCore is fully implemented and longer-term results are realized.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CLINICAL TRIAL: PHASE I CLINICAL AND PHARMACOKINETIC TRIAL OF INTRAPERITONEAL IR
PHII-51: A RANDOMIZED PHASE 2 NON-COMPARATIVE STUDY OF SB-715992 GIVEN WEEKLY
Protocol Review and Monitoring System
Protocol Review and Monitoring System
海外基金